Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.57 |
| ▸ | MAOA | P21397 | 4/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.46 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.46 |
| ▸ | TUBB | P07437 | 1/20 | 0.46 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.46 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.46 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.46 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.46 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.46 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.46 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.46 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.46 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.46 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.46 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.46 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.46 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6199828 | 0.93 | PTGS2 (0.56) | ACHEMAOAPTGS2CHRNA7 | |
| SCHEMBL3081446 | 0.93 | PTGS2 (0.59) | ACHEMAOAPTGS2PBRM1CHRNA7 | |
| SCHEMBL661560 | 0.90 | ACHE (0.54) | ACHEMAOAPTGS2TUBB4ATUBB | |
| SCHEMBL9620643 | 0.90 | ACHE (0.54) | ACHEMAOAPTGS2CHRNA7 | |
| SCHEMBL29420326 | 0.85 | KMT2A (0.56) | ACHEMAOATUBB4ATUBBTUBA3C | |
| SCHEMBL29420327 | 0.85 | KMT2A (0.56) | ACHEMAOATUBB4ATUBBTUBA3C | |
| SCHEMBL354177 | 0.85 | KMT2A (0.56) | ACHEMAOATUBB4ATUBBTUBA3C | |
| SCHEMBL7637138 | 0.84 | ACHE (0.49) | ACHEMAOAPTGS2CHRNA7MIF | |
| SCHEMBL1545375 | 0.83 | ACHE (0.54) | ACHEMAOAPTGS2CHRNA7 | |
| SCHEMBL1274990 | 0.83 | ACHE (0.54) | ACHEMAOAPTGS2CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3680237-A1 | PROCESS FOR PREPARING SUBSTITUTED 2,3-DIHYDRO-1H-INDEN-1-ONE RETINOIC ACID-RELATED ORPHAN NUCLEAR RECEPTOR ANTAGONISTS FOR TREATING MULTIPLE SCLEROSIS | Arrien Pharmaceuticals LLC (US) | 2020-07-15 | — | — | EP | disclosed |
| US-10682358-B2 | Substituted 2, 3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis | ARRIEN PHARMACEUTICALS LLC (US) | 2020-06-16 | — | — | US | disclosed |
| EP-3044223-B1 | 2,3-DIHYDRO-1H-INDEN-1-ONE DERIVATIVES AS RETINOIC ACID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA) ANTAGONISTS FOR TREATING MULTIPLE SCLEROSIS | ARRIEN PHARMACEUTICALS LLC (US) | 2020-04-01 | — | — | EP | disclosed |
| US-20190209574-A1 | SUBSTITUTED 2, 3-DIHYDRO-1H-INDEN-1-ONE RETINOIC ACID-RELATED ORPHAN NUCLEAR RECEPTOR ANTAGONISTS FOR TREATING MULTIPLE SCLEROSIS | ARRIEN PHARMACEUTICALS LLC (US) | 2019-07-11 | — | — | US | disclosed |
| US-10172866-B2 | Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis | ARRIEN PHARMACEUTICALS LLC (US) | 2019-01-08 | — | — | US | disclosed |
| EP-1583738-B1 | INDENONCARBOXYLIC ACIDS DERIVATIVES AND THEIR USE FOR THE TREATMENT OF AND PREVENTING DIABETES AND DYSLIPIDAEMIA | MERCK PATENT GMBH (DE) | 2017-05-10 | — | — | EP | disclosed |
| US-20160213627-A1 | Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis | XENTHERA, INC. | 2016-07-28 | — | — | US | disclosed |
| US-20160213676-A1 | Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis | XENTHERA, INC. | 2016-07-28 | — | — | US | disclosed |
| US-9359315-B2 | Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis | ARRIEN PHARMACEUTICALS LLC (US) | 2016-06-07 | — | — | US | disclosed |
| EP-1740579-B1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-20020002161-A1 | Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds | PHARMACIA & UPJOHN COMPANY | 2002-01-03 | — | — | US | disclosed |
| WO-2001072752-A2 | 2,3,4,5-TETRAHYDRO-1H-[1,4]DIAZEPINO[1,7-a]INDOLE COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 2001-10-04 | — | — | WO | disclosed |
| US-5648381-A | Derivatives of indan-1,3-dione and indan-1,2,3-trione, methods of preparing them and therapeutic use thereof | INNOTHERA (FR) | 1997-07-15 | — | — | US | disclosed |
| US-5571843-A | Derivatives of indan-1,3-dione and indan-1,2,3-trione, methods of preparing them and therapeutic use thereof | INNOTHERA (FR) | 1996-11-05 | — | — | US | disclosed |
| EP-0566445-B1 | Derivatives of indane 1,3-dione and indane-1,2,3-trione, processes for their preparation and their application in therapy | INNOTHERA LAB SA (FR) | 1996-02-07 | — | — | EP | disclosed |
| EP-0566446-B1 | Derivatives of indane-1,3-dione and indane-1,2,3-trione, processes for their preparation and their application in therapy | INNOTHERA LAB SA (FR) | 1996-02-07 | — | — | EP | disclosed |
| EP-0566445-A1 | Derivatives of indane 1,3-dione and indane-1,2,3-trione, processes for their preparation and their application in therapy | INNOTHERA (FR) | 1993-10-20 | — | — | EP | disclosed |
| EP-0566446-A1 | Derivatives of indane-1,3-dione and indane-1,2,3-trione, processes for their preparation and their application in therapy | INNOTHERA (FR) | 1993-10-20 | — | — | EP | disclosed |
| WO-1993020045-A1 | INDAN-1,3-DIONE AND INDAN-1,2,3-TRIONE DERIVATIVES, PROCESSES FOR THE PREPARATION OF SAME AND THEIR APPLICATION AS THERAPEUTIC AGENTS | INNOTHERA (FR) | 1993-10-14 | — | — | WO | disclosed |
| WO-1993020046-A1 | INDAN-1,3-DIONE AND INDAN-1,2,3-TRIONE DERIVATIVES, PROCESSES FOR PREPARATION OF SAME AND THEIR USE AS THERAPEUTIC AGENTS | INNOTHERA (FR) | 1993-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10682358-B2 | Substituted 2, 3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis | RORA, RORB, RORC | ACHE 925/4885MAOA 4252/4885PTGS2 1215/4885 |
| US-10172866-B2 | Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis | RORA, RORB, RORC | ACHE 925/4885MAOA 4252/4885PTGS2 1215/4885 |
| US-20020002161-A1 | Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds | HTR1D, HTR1A, HTR1E | ACHE 271/4885MAOA 87/4885PTGS2 1052/4885 |
| US-20160213627-A1 | Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis | RORA, RORB, RORC | ACHE 925/4885MAOA 4252/4885PTGS2 1215/4885 |
| US-20190209574-A1 | SUBSTITUTED 2, 3-DIHYDRO-1H-INDEN-1-ONE RETINOIC ACID-RELATED ORPHAN NUCLEAR RECEPTOR ANTAGONISTS FOR TREATING MULTIPLE SCLEROSIS | RORA, RORB, RORC | ACHE 925/4885MAOA 4252/4885PTGS2 1215/4885 |
| US-20160213676-A1 | Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis | RORA, RORB, RORC | ACHE 925/4885MAOA 4252/4885PTGS2 1215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.